The Manufacturers Life Insurance Company Buys 53,490 Shares of Oric Pharmaceuticals, Inc. $ORIC

The Manufacturers Life Insurance Company increased its stake in shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) by 41.6% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 182,139 shares of the company’s stock after acquiring an additional 53,490 shares during the period. The Manufacturers Life Insurance Company’s holdings in Oric Pharmaceuticals were worth $2,308,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its position in Oric Pharmaceuticals by 48.8% during the third quarter. Vanguard Group Inc. now owns 4,650,138 shares of the company’s stock worth $55,802,000 after purchasing an additional 1,525,445 shares during the period. State Street Corp raised its position in shares of Oric Pharmaceuticals by 77.1% in the fourth quarter. State Street Corp now owns 4,258,397 shares of the company’s stock valued at $34,834,000 after purchasing an additional 1,854,458 shares during the period. Orbimed Advisors LLC raised its position in shares of Oric Pharmaceuticals by 305.0% in the third quarter. Orbimed Advisors LLC now owns 3,641,756 shares of the company’s stock valued at $43,701,000 after purchasing an additional 2,742,475 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Oric Pharmaceuticals by 14.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,295,122 shares of the company’s stock valued at $26,955,000 after purchasing an additional 423,795 shares during the period. Finally, Siren L.L.C. lifted its stake in shares of Oric Pharmaceuticals by 197.6% in the first quarter. Siren L.L.C. now owns 2,998,192 shares of the company’s stock worth $37,987,000 after buying an additional 1,990,617 shares during the last quarter. 95.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ORIC. Stifel Nicolaus assumed coverage on shares of Oric Pharmaceuticals in a research note on Friday, June 12th. They issued a “buy” rating and a $14.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of Oric Pharmaceuticals in a research report on Monday, June 8th. Benchmark restated a “buy” rating on shares of Oric Pharmaceuticals in a report on Monday, June 8th. Wall Street Zen raised Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 25th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Oric Pharmaceuticals in a research note on Friday, May 22nd. Thirteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.27.

Oric Pharmaceuticals Trading Up 4.4%

Shares of Oric Pharmaceuticals stock opened at $13.50 on Friday. The company’s fifty day simple moving average is $10.15 and its 200-day simple moving average is $10.47. The company has a market cap of $1.40 billion, a price-to-earnings ratio of -10.00 and a beta of 1.02. Oric Pharmaceuticals, Inc. has a 1 year low of $7.23 and a 1 year high of $14.93.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its earnings results on Monday, August 3rd. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.02). As a group, research analysts forecast that Oric Pharmaceuticals, Inc. will post -1.51 earnings per share for the current fiscal year.

Oric Pharmaceuticals Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.